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AbsTrACT 
background tumour necrosis factor alpha (tnF-α) is 
a pleiotropic cytokine with both injurious and protective 
functions, which are thought to diverge at the level of 
its two cell surface receptors, tnFr1 and tnFr2. in the 
setting of acute injury, selective inhibition of tnFr1 is 
predicted to attenuate the cell death and inflammation 
associated with tnF-α, while sparing or potentiating the 
protective effects of tnFr2 signalling. We developed a 
potent and selective antagonist of tnFr1 (gSK1995057) 
using a novel domain antibody (dab) therapeutic and 
assessed its efficacy in vitro, in vivo and in a clinical trial 
involving healthy human subjects.
Methods We investigated the in vitro effects of 
gSK1995057 on human pulmonary microvascular 
endothelial cells (HMVec-l) and then assessed the effects 
of pretreatment with nebulised gSK1995057 in a non-
human primate model of acute lung injury. We then tested 
translation to humans by investigating the effects of a single 
nebulised dose of gSK1995057 in healthy humans (n=37) 
in a randomised controlled clinical trial in which subjects 
were subsequently exposed to inhaled endotoxin.
results Selective inhibition of tnFr1 signalling 
potently inhibited cytokine and neutrophil adhesion 
molecule expression in activated HMVec-l monolayers 
in vitro (P<0.01 and P<0.001, respectively), and also 
significantly attenuated inflammation and signs of lung 
injury in non-human primates (P<0.01 in all cases). 
in a randomised, placebo-controlled trial of nebulised 
gSK1995057 in 37 healthy humans challenged with 
a low dose of inhaled endotoxin, treatment with 
gSK1995057 attenuated pulmonary neutrophilia, 
inflammatory cytokine release (P<0.01 in all cases) and 
signs of endothelial injury (P<0.05) in bronchoalveolar 
lavage and serum samples.
Conclusion these data support the potential for 
pulmonary delivery of a selective tnFr1 dab as a 
novel therapeutic approach for the prevention of acute 
respiratory distress syndrome.
Trial registration number  clinicaltrials. gov 
nct01587807.
InTroduCTIon
Acute respiratory distress syndrome (ARDS) affects 
approximately 190 000 patients per annum in the 
USA, and is associated with mortality rates of up to 
40%.1 To date, no effective pharmacological thera-
pies, which target the underlying pathophysiological 
mechanisms of ARDS, have been discovered.2 The 
development of ARDS is characterised by immune 
cell-mediated injury to the lung,3 4 associated with 
the release of inflammatory cytokines and prote-
ases. The uncontrolled local inflammatory response 
in ARDS contributes to alveolar-capillary barrier 
damage and the exudation of protein-rich fluid into 
the alveolar space, which manifests as non-cardio-
genic pulmonary oedema.5 Pulmonary neutrophil 
recruitment, which is central to the pathogenesis of 
ARDS, is mediated by the interaction of primed and 
activated neutrophils with the lung microvascular 
endothelium.6 Preclinical and clinical studies have 
identified tumour necrosis factor alpha (TNF-α) as 
a key effector molecule in ARDS and also sepsis; a 
Key messages
What is the key question?
 ► Does selectively targeting tumour necrosis 
factor receptor 1 (TNFR1) signalling with a 
novel domain antibody (dAb) reduce pulmonary 
inflammation?
What is the bottom line?
 ► A dAb selective to the TNFR1 reduced 
pulmonary inflammation in both non-human 
primate and human pulmonary endotoxin 
challenge models when dosed prophylactically. 
Data from mechanistic studies in human cells 
with this dAb support the importance of TNFR1 
signalling in mediating endothelial–neutrophil 
interactions associated with the development 
of lung injury.
Why read on?
 ► This investigation provides original data to 
support the utility of a novel TNFR1-targeting 
dAb as a potential therapy in patients with 
acute respiratory distress syndrome and 
supports further clinical investigation in 
patients.
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common cause of ARDS.7 8 However, results from clinical trials 
of parenteral non-selective TNF-α targeting antibodies in sepsis 
have been variable with most failing to demonstrate a significant 
survival benefit9–12; at least one trial suggesting evidence of harm 
at higher doses13; and one trial suggesting an improvement in 
hospital survival and organ dysfunction in patients with elevated 
baseline interleukin-6 (IL-6) levels.14 
Recently, it has become evident that the pleiotropic effects of 
TNF-α diverge at the level of its two cellular receptors, TNF 
receptor 1 (TNFR1) and TNF receptor 2 (TNFR2).15 Whereas 
numerous studies support the role of TNFR1 in mediating 
cell death signalling and inflammation,16 the role of TNFR1 
in the generation of vascular leak and neutrophilic inflamma-
tion remains controversial.17 18 In contrast, it has recently been 
suggested that TNFR2 signalling may be important in attenuating 
the apoptotic activity of TNF-α, and in mediating important 
survival and proliferation signals19–21 through activation of apop-
totic regulators (eg, cIAP1 and 2) and the non-canonical nuclear 
factor κB pathway, respectively.22 Interestingly, TNFR1-deficient 
mice are protected from lung injury, sepsis and other acute organ 
injuries, whereas TNFR2-deficient mice are consistently more 
susceptible to injury in these models.20 23–26 These studies indi-
cate that selectively antagonising TNFR1, while sparing TNFR2 
signalling, could be therapeutically advantageous. We therefore 
developed a short-acting, fully human domain antibody (dAb) 
fragment that selectively antagonises TNF-α signalling through 
TNFR1, but not TNFR2.
dAbs represent the smallest functional antigen-binding units 
of human antibodies (10–13 kDa), are derived from single vari-
able regions of either heavy or light chain sequences of human 
IgG and are sufficiently stable to allow nebulisation directly 
to the lungs.27 A homology model structure and amino acid 
sequence of GSK1995057 are shown in online supplementary 
figure 1, together with binding characteristics to both human 
and cynomolgus monkey TNFR1-Fc fusion proteins. When 
administered directly to the lungs of mice either concomitantly 
or after challenge with acid instillation or ventilation with large 
tidal volumes, murine TNFR1-targeting dAbs attenuate the 
development of pulmonary oedema, arterial hypoxaemia and 
inflammation.28 29 Here we present the first report of an inhaled 
variable heavy (VH) chain TNFR1 dAb antagonist (GSK1995057) 
administered directly to the lungs of cynomolgus monkeys and 
humans, and explore the underlying mechanism of action using 
in vitro human tissue assays.
MeThods
In vitro studies in human cells
The assessment of permeability of human pulmonary microvas-
cular endothelial cell (HMVEC-L) monolayers was undertaken 
using an electrical cell impedance sensor technique. Once elec-
trical resistance achieved steady state, cells were incubated for 
1 hour in the presence of GSK1995057 or dummy dAb (10 nM) 
or vehicle control for 1 hour prior to stimulation with TNF-α 
(10 ng/mL). Neutrophil transmigration assays were performed 
using neutrophils isolated from healthy volunteers. Neutro-
phil transmigration through confluent HMVEC-L incubated 
with GSK1995057 or dummy dAb (10 nM) or vehicle control 
for 1 hour prior to stimulation with TNF-α (10 ng/mL) was 
measured using CytoSelect Leukocyte Transmigration assay 
(Cambridge Biosciences) and endothelial ligand cell surface 
expression was assessed using HMVEC-L after 4 hours of treat-
ment. Detailed descriptions of assay conditions are contained 
in the online supplementary data. Samples were analysed on a 
FACSCanto II flow cytometer (BD Biosciences) as described in 
the online supplementary data. In all in vitro experiments with 
GSK1995057 were compared with a non-targeting ‘dummy 
dAb’ comprising natural human VH framework sequences and 
‘scrambled’/non-sense hypervariable domains.
In vivo study in cynomolgus monkeys
The objective of this study was to investigate the dose–response 
relationship of single doses of GSK1995057 given as a pretreat-
ment in a lipopolysaccharide (LPS)-induced model of pulmonary 
inflammation in sedated young adult cynomolgus monkeys. The 
primary endpoint was neutrophil counts in bronchoalveolar 
lavage fluid (BALF) at 6 and 24 hours after dosing.
Animal husbandry
Animals were housed according to the USDA Animal Welfare 
Act (9 CFR, parts 1, 2 and 3) and as described in the Guide 
for the Care and Use of Laboratory Animals.30 Temperatures of 
18°C–29°C (64°F–84°F) with a relative humidity of 50%±20% 
were maintained, along with 10 or greater air changes per 
hour with 100% fresh air (no air recirculation), and a 12-hour 
light/12-hour dark cycle. LabDiet Certified Primate Diet 5048 
was fed to the animals daily, supplemented with washed, fresh 
produce. Before anaesthesia, animals were fasted for a minimum 
of 4 hours. Reverse-osmosis, postchlorinated water was provided 
ad libitum, including during times of fasting.
Study procedures
A description of the methodology for administration of anaes-
thesia and LPS is present in the online supplementary data. One 
hour after administration of GSK1995057, or vehicle, LPS Esch-
erichia coli serotype 055:B5 (4 mL of 100 µg/mL) was admin-
istered via aerosolisation (DeVilbiss Ultraneb-99 ultrasonic 
nebuliser) over 5 min. Blood and bronchoalveolar lavage (BAL) 
samples were collected at baseline (before challenge), 6 and 
24 hours after LPS challenge. Detailed descriptions of the tech-
niques used for bronchoscopy and bronchoalveolar lavage are 
contained within the online supplementary data.
Biomarker assays
Cynomolgus monkey BAL samples were analysed by Myriad 
RBM using their Multi-Analyte Platform (MAP) technology on 
the Human MAPv1.6 panel of 89 biomarkers, 78 of which are 
confirmed to be cynomolgus monkey cross-reactive.
Study approval
All studies were conducted in accordance with the GSK Policy on 
Care, Welfare, and Treatment of Laboratory Animals, and were 
reviewed by the Institutional Animal Care and Use Committee at 
Charles River Laboratories.
Clinical trial in healthy volunteers
Participants
Healthy subjects were recruited by advertising. Screening 
consisted of a history and physical examination, blood investiga-
tions, ECG and spirometry (full clinical trial protocol inclusion 
and exclusion criteria and study schedule are outlined in the data 
file and table E1, respectively, in the online supplementary data).
Study design
The clinical trial was a randomised, placebo-controlled study to 
investigate the safety, tolerability, pharmacokinetics and pharma-
codynamics of single doses of inhaled GSK1995057 in healthy 
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subjects. The study consisted of 2 parts within a ‘fused’ protocol 
operated across two different clinical units, recruiting a total of 
six cohorts. The dose-escalating cohorts in part 1 were conducted 
to confirm preliminary safety, tolerability and pharmacokinetics 
of GSK1995057 and were conducted at the PAREXEL Inter-
national Clinical Pharmacology Research Unit, Harrow, UK. 
This part of the study was conducted in a single-blind manner 
to allow appropriate, real-time assessment of safety. Subjects in 
cohort 5 of part 1 received a single inhaled dose of GSK1995057 
in addition to BAL sampling at approximately 30 min after dose 
to confirm BALF levels of GSK1995057.
Subjects in part 2 of the trial were randomised to receive a 
single nebulised dose (26 mg) of GSK1995057 1 hour prior to 
receiving a nebulised challenge of 50 µg of E. coli LPS. This part 
of the study was carried out at Celerion Clinical Pharmacology 
Unit, Belfast, UK. The BAL procedure was performed 6 hours 
after LPS inhalation (7 hours after dosing GSK1995057) and the 
primary endpoint of the trial was BALF neutrophil count with 
BALF and plasma cytokine, chemokine, epithelial and endothelial 
biomarkers as secondary endpoints. The dose of GSK1995057 
and timing for BAL was derived from data obtained from the 
dose-finding study in cynomolgus monkeys also presented in this 
manuscript. A detailed description of the study design, admin-
istration of the study drug, bronchoscopy, BAL and sample 
collection are contained within the online supplementary data. 
Pharmacokinetic sampling was performed at varying time points 
up to 48 hours after the start of nebulisation of GSK1995057, 
and concentrations of GSK1995057 in plasma and BALF were 
measured by electrochemiluminescence immunoassay (ECLIA) 
on the MesoScale Discovery (MSD) platform (Gaithersburg, 
MD, USA) (lower limit of quantification=100 ng/mL).
Biomarker assays
The measurement of biomarkers in BALF and serum samples 
from the clinical trial participants were tested under contract by 
Myriad RBM (Austin, Texas, USA) using their proprietary multi-
plex Luminex immunoassay platform; the human inflammation 
multiplex MAP (iMAP). Biomarkers of interest not included 
on this panel were measured using commercial ELISAs (surfac-
tant protein-D (SP-D) and Club cell secretory protein (CC16) 
ELISAs from BioVendor), following manufacturers’ recommen-
dations under contract by Quotient BioResearch (Fordham, 
Cambridgeshire, UK). Changes from baseline in free and total 
TNFR1 were evaluated at varying time points up to 48 hours 
after the start of nebulisation using an ECLIA on the MSD plat-
form and were conducted by GSK.
Study approval
The study was undertaken in accordance with the Declaration of 
Helsinki and ICH GCP. Written informed consent was obtained 
from all subjects prior to enrolment in the study.
Statistical analysis
Analysis of non-clinical data from in vitro and in vivo studies 
with GSK1995057 was undertaken using analysis of variance on 
appropriately transformed data, with the exception of neutrophil 
migration data (figure 1A) and soluble E-selectin data (figure E2a 
in the online supplementary data) for which a non-parametric 
analysis (Kruskal-Wallis rank-sum test) was necessary. P<0.05 
was accepted as a significant difference between comparisons. 
All data are presented as geometric mean and SE and no multi-
plicity adjustments were made.
The clinical trial was designed to recruit enough subjects 
to provide data from 36 subjects available for analysis (18 for 
placebo, and 18 for GSK1995057). While the sample size was 
based on feasibility, subject numbers were determined to ensure 
at least 80% power to detect a 65% decrease in BALF neutro-
phil counts based on mean effect sizes observed in monkey LPS 
challenge studies. An interim sample size re-estimation (blinded 
to investigator site team) was undertaken when BAL neutrophil 
counts from 16 subjects (eight in each study arm) were available 
for statistical analysis. This confirmed the estimates used to assess 
the statistical power of the planned sample size, and therefore no 
change to the sample size was made. Distributional assumptions 
were assessed by visual inspection of residual plots. Normality 
was examined by normal probability plots, while homogeneity 
of variance was assessed by plotting the residuals against the 
predicted values for the model. Two sample t-tests were used 
to evaluate the effects of GSK1995057 on biomarkers from 
BALF samples. Mixed model repeated measures using random 
effects was used to evaluate the effects of GSK1995057 on 
biomarkers from serum samples using SAS V.9.3. Baseline values 
of the biomarker were included as covariates in the analysis of 
biomarkers from serum samples. Data are shown as geometric 
mean and SE.
resulTs
TnFr1-mediated neutrophil–endothelial cell interactions in 
vitro
To investigate the hypothesis that TNFR1 mediates neutrophilic 
inflammation in the lung, we assessed the impact of selective 
TNFR1 antagonism using GSK1995057 on neutrophil trans-
migration and endothelial permeability in a human in vitro cell 
system. Using the CytoSelect Leukocyte Transmigration assay, 
we observed that pretreatment of HMVEC-L monolayers with 
GSK1995057 significantly reduced the transendothelial migra-
tion of neutrophils towards the neutrophil chemoattractant IL-8 
(figure 1A; P<0.05). GSK1995057 also reduced TNF-α-me-
diated endothelial permeability (figure 1B; P<0.001), and 
modulated the expression of key ligands for neutrophil–endo-
thelial interaction, preventing the TNF-α-induced increases 
in HMVEC-L surface expression of E-selectin, intercellular 
adhesion molecule (ICAM)-1 and vascular cell adhesion mole-
cule (VCAM)-1 (P<0.001 in all cases; figure 1C–E), as well as 
decreasing the concentrations of the soluble forms of these mole-
cules, which are markers of endothelial injury (P<0.05 in all 
cases; see online supplementary figure 2). TNFR1 antagonism 
also reduced the release of the cytokines IL-1β, IL-6 and IL-8 by 
TNF-α-stimulated HMVEC-L (P<0.01 in all cases; see online 
supplementary figure 3).
TnFr1 inhibition with GsK1995057 prevented acute lung 
injury in a non-human primate model
We investigated further the effects of a single aerosolised dose 
of GSK1995057 on pulmonary inflammation in a non-human 
primate model of acute lung injury. Twenty-five cynomolgus 
monkeys received either nebulised vehicle control, nebulised 
GSK1995057 (0.043 mg, 0.45 mg or 4.7 mg) or an instillation 
of fluticasone propionate (positive control; 1.2 mg) via the intra-
tracheal route, 1 hour prior to nebulised LPS (400 µg) challenge. 
Nebulised GSK1995057 was well tolerated in monkeys and no 
adverse effects associated with dosing were observed (data not 
shown). The primary endpoint was the number of neutrophils in 
the BALF at 6 and 24 hours after LPS exposure. BALF neutro-
phil counts were markedly suppressed at 6 hours for all three 
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doses of GSK1995057, and at 24 hours for the higher dose levels 
(0.45 and 4.7 mg (P<0.01 in all cases; figure 2A)). In support 
of this finding, the BALF concentration of neutrophil-derived 
myeloperoxidase was also reduced in the GSK1995057-treated 
animals (see online supplementary figure 4A). A reduction in 
BALF monocyte-macrophage numbers was also observed at 
24 hours, reaching significance with the highest and middle 
doses of GSK1995057 (P<0.01, online supplementary figure 
4B). In agreement with our in vitro studies, pretreatment with 
GSK1995057 reduced the BALF concentration of alpha-2-mac-
roglobulin, a marker of alveolar-capillary barrier permeability 
(figure 2B) and von Willebrand factor, a biomarker of endothe-
lial injury/activation (vWF; figure 2C). Selective TNFR1 antag-
onism with GSK1995057 also reduced BALF concentrations of 
IL-1β, IL-6 and IL-8, compared with vehicle-treated animals 
(P<0.05 in all cases; figure 2D–F).
TnFr1 inhibition with GsK1995057 prevented acute lung 
injury in a healthy human volunteer model
Having demonstrated that selective TNFR1 antagonism with 
GSK1995057 reduced neutrophilic pulmonary inflammation, 
microvascular permeability and endothelial cell activation/injury 
in complementary in vitro and in vivo models, we undertook 
a double-blinded, placebo-controlled clinical trial to determine 
the effects of nebulised GSK1995057 in an LPS-induced model 
of acute lung injury in healthy human volunteers. Previous clin-
ical investigations with intravenous GSK1995057 identified a 
pre-existing host antibody response in some human subjects that 
increased the risk of mild infusion reactions following intrave-
nous dosing.31 As a result, only healthy subjects prospectively 
demonstrated to be seronegative for these pre-existing antidrug 
antibodies were eligible for participation. Following a dose 
escalation study to determine the safety, tolerability, pharmaco-
kinetics and target engagement of nebulised GSK1995057 (see 
online supplementary figures 5–7), healthy human subjects were 
randomised (1:1) to receive a single nebulised dose (26 mg) of 
GSK1995057 or placebo (see online supplementary table 2 for 
details of investigational products), administered 1 hour prior to 
the inhalation of LPS (50 µg), with BALF collected 6 hours after 
LPS challenge ( ClinicalTrials. gov identifier NCT01587807). The 
LPS challenge schema is outlined in online supplementary figure 
8, and the full study schedule is shown in online supplementary 
table 1. The primary endpoint of the study was the BALF neutro-
phil count 6 hours after LPS exposure (7 hours after dosing of 
GSK1995057).
Thirty-seven healthy subjects were enrolled. One subject 
in the placebo group was excluded from cell count analyses, 
due to technical failure of automated cell counting. Since the 
Figure 1 Effects of GSK1995057 on neutrophil–human pulmonary microvascular endothelial interactions in vitro. Panel (A) shows the effects of 
GSK1995057 on the transmigration of Leukotracker labelled human neutrophils towards interleukin (IL)-8, through TNF-α-treated human pulmonary 
microvascular endothelial cell monolayers. Panel (B) shows the effect of GSK1995057 on the transendothelial resistance, a marker of permeability, 
of TNF-α-treated human pulmonary microvascular monolayers. Panels (C–E) show the effect of GSK1995057 on the cell surface expression of the 
key neutrophil ligands E-selectin, ICAM-1 and VCAM-1 by TNF-α-treated human pulmonary microvascular monolayers. Data shown are geometric 
mean±SEM ((A) n=6; (B) n=6 (dummy dAb condition n=3); (C–E) n=4). Data analysed with analysis of variance (ANOVA) or Kruskal-Wallis rank-sum 
test (A). *P<0.05; **P<0.01; ***P<0.001. AU, arbitrary units; dAb, domain antibody; ICAM, intercellular adhesion molecule; TNF, tumour necrosis 
factor; VCAM, vascular cell adhesion molecule. 
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sample was otherwise viable, protein biomarker results from 
this subject were included in the analyses, but an additional 
subject was recruited to the placebo group to provide addi-
tional cell count data. The Consolidated Standards of Reporting 
Trials diagram for the study is shown in figure 3A. There were 
no differences in baseline demographic parameters between 
the groups randomised to receive placebo or GSK1995057 
(figure 3B). No serious or unexpected adverse events occurred 
in either group. The table of adverse events is shown in online 
supplementary table 3.
Figure 2 Effects of GSK1995057 in a non-human primate experimental model of acute lung injury. Cynomolgus monkeys received nebulised 
GSK1995057 (0.043, 0.45 or 4.7 mg), vehicle control, or an intratracheal instillation of fluticasone propionate (FP) (positive control; 1.2 mg), 1 hour 
prior to nebulised lipopolysaccharide (LPS; 4 mL of 100 µg/mL) challenge. Bronchoalveolar lavage fluid (BALF) was collected at 6 and 24 hours after 
LPS challenge. The effects of inhaled GSK1995057 (0.043, 0.45 or 4.7 mg dose) are shown on BALF neutrophil counts, and BALF concentrations of 
the alveolar-capillary permeability marker alpha-2-macroglobulin and the biomarker of endothelial activation/injury von Willebrand factor (A–C). 
Panels (D–F) show the effects of GSK1995057 on BALF concentrations of interleukin (IL)-1β, IL-6 and IL-8, respectively. Data shown are geometric 
means±SEM (n=3 monkeys in the FP group, n=5 in the 4.7 mg GSK1995057 and vehicle groups, and n=6 in the 0.45 and 0.043 mg GSK1995057 
groups). Data analysed with analysis of variance (ANOVA). *P<0.05; **P<0.01; ***P<0.001. 
Figure 3 Consolidated Standards of Reporting Trials (CONSORT) diagram for clinical trial and baseline characteristics of study subjects. Panel (A) 
shows the CONSORT diagram for the double-blinded, placebo-controlled, clinical study of GSK1995057 in healthy volunteers exposed to inhaled 
lipopolysaccharide (LPS). Panel (B) details the baseline characteristics of the subjects recruited to the clinical study.
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Pretreatment with GSK1995057 was associated with a reduc-
tion in the post-LPS BALF neutrophil count compared with 
placebo (figure 4A). This reduction became statistically signifi-
cant when a single biological outlier who received GSK1995057 
and exhibited an exaggerated increase in BALF neutrophils (>3 
times IQR, and outside the upper quartile) was excluded (41% 
reduction, P<0.05 vs placebo; figure 4B). BALF cytology in this 
subject was abnormal with the presence of foamy macrophages, 
excessive mucus and debris, and lytic/apoptotic neutrophils; 
however, the subject was clinically well other than a transient 
fever (38.2°C) 13 and 14 hours after administration of LPS and 
GSK1995057, respectively, which was considered consistent 
with the expected clinical effects of LPS challenge. The BALF 
neutrophil data are presented both with and without this biolog-
ical outlier. GSK1995057 had no effect on the numbers of 
macrophages or lymphocytes within the BALF at 6 hours (data 
not shown).
In keeping with our in vitro and animal model studies, 
GSK1995057 significantly reduced the BALF concentrations of 
IL-1β, IL-6 and IL-8 following LPS administration (P<0.01 in 
all cases; figure 4D–F), as well as reducing BALF concentrations 
of the mononuclear cell chemokines MIP1α, MIP1β and MCP-1 
(P<0.001 in all cases; online supplementary figure 9A–C). 
Furthermore, GSK1995057 also reduced the BALF concen-
tration of vWF after LPS challenge (P<0.05; figure 4C). This 
occurred in the absence of alterations in the BALF concentrations 
of the alveolar epithelial injury/activation markers SP-D and 
CC16; data not shown. These data again support the concept 
that GSK1995057 reduces pulmonary inflammation via modu-
lation of neutrophil–endothelial interactions. We observed no 
differences in the BALF concentrations of the alveolar-capillary 
barrier permeability marker alpha-2-macroglobulin between 
placebo and GSK1995057-treated subjects (data not shown). 
Of note, however, the dose of LPS used in the human clinical 
trial was much lower than that used in the animal study where 
amelioration of LPS-induced permeability by GSK1995057 was 
observed (50 µg in humans vs 400 µg in animals). The increase 
in serum C-reactive protein 24 hours after LPS challenge was 
significantly attenuated by pretreatment with GSK1995057 
(P<0.001; online supplementary figure 10), which was consis-
tent with effects on the systemic acute phase response. Pharma-
cokinetic data demonstrated that inhaled doses of GSK1995057 
reached the lung and subsequently, to a lesser extent, the systemic 
compartment (online supplementary figure 6).
dIsCussIon
Here we demonstrate that GSK1995057 reduced pulmonary 
inflammation in non-human primate and human models of 
ARDS, and confirm a mechanistic link between TNFR1 signal-
ling and neutrophil/endothelial interactions. The observation 
that GSK1995057 significantly blunted neutrophil migration 
Figure 4 Effects of GSK1995057 in a human experimental model of acute lung injury. Healthy human subjects (n=37) were randomised (1:1) to 
treatment with GSK1995057, or vehicle control, 1 hour prior to inhalation of 50 µg lipopolysaccharide (LPS). Bronchoalveolar lavage fluid (BALF) 
was collected 6 hours after LPS inhalation. The effect of GSK1995057 on BALF neutrophil count is shown with (A) and without (B) a single biological 
outlier who displayed an exaggerated increase in BALF neutrophils (>3 times IQR, and outside the upper quartile). BALF cytology in this subject was 
abnormal with the presence of foamy macrophages, excessive mucus and debris, and lytic/apoptotic neutrophils; however, the subject was clinically 
well and had a transient increase in temperature (38.2°C) after LPS inhalation, but no clinically significant adverse events. Panel (C) shows the 
effect of GSK1995057 on BALF concentration of the endothelial activation/injury biomarker von Willebrand factor. Panels (D–F) show the effect of 
GSK1995057 on BALF concentrations of interleukin (IL)-1β, IL-6 and IL-8, respectively. Data shown are geometric means±SEM (n=18 subjects per 
treatment group). Data analysed with two-sample t-test. *P<0.05; **P<0.01 compared with placebo.
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through endothelial monolayers in vitro suggests an important 
role for TNFR1 in mediating neutrophil–endothelial interac-
tions, possibly by regulating the cell surface expression of endo-
thelial cell adhesion molecules E-selectin, ICAM and VCAM. 
In patients with ARDS, neutrophil infiltration into the lungs is 
further augmented by a compromised alveolar-capillary barrier 
brought about by the action of proinflammatory mediators.32 
Consistent with previous reports,17 18 33 we showed that TNF-α 
contributed to increased endothelial permeability and found that 
GSK1995057 prevented this increase, suggesting that TNFR1 
signalling (rather than TNFR2 signalling) mediates TNF-in-
duced endothelial permeability.
In some patients with ARDS, it may be sufficient to deliver 
short-acting therapeutics directly to the lungs; however, 
factors influencing the pulmonary delivery and disposition of 
antibodies or antibody fragments are complex,34 with limited 
precedence in humans. We therefore sought to determine 
whether nebulised GSK1995057 could be delivered to lungs 
efficiently, and whether the effects observed in in vitro assays 
could be recapitulated in vivo. To test this, we used the well-es-
tablished model of lung LPS challenge to trigger a clinically 
relevant and complex inflammatory response to model subclin-
ical tissue injury.35–37 In monkeys exposed to a single inhaled 
LPS challenge, pretreatment with nebulised GSK1995057 
significantly reduced pulmonary neutrophil infiltration, levels 
of proinflammatory chemokines, markers of endothelial injury 
and alveolar-capillary leak in a dose-dependent fashion. These 
data are consistent with a single report of the effects of full 
IgG anti-TNF-α monoclonal antibodies in similar non-human 
primate models,38 and suggest an important role for TNFR1 
signalling in the control of neutrophilic inflammation in vivo. 
Moreover, the data suggest that like other inhaled antibody 
approaches, low doses of inhaled GSK1995057 may deliver 
the same or more potent effects in the lung as higher doses of 
parenterally administered antibodies.39 Finally, we sought to 
translate our findings with GSK1995057 to human subjects 
through the conduct of a clinical trial in which healthy 
subjects were exposed to a low dose of inhaled LPS following 
a single nebulised dose of GSK1995057. Consistent with our 
investigations in monkeys, healthy subjects pretreated with 
GSK1995057 experienced less neutrophilic lung inflamma-
tion, and signs of endothelial injury in response to LPS chal-
lenge than subjects who received placebo. Subjects pretreated 
with GSK1995057 also showed signs of reduced systemic 
inflammation. Taken together, these studies highlight the ther-
apeutic potential of GSK1995057, and the involvement of 
TNFR1 signalling in inflammation and tissue injury responses 
in primates and humans.
The current study has limitations. While BAL protein 
increased 24 hours after LPS challenge in monkeys, and 
GSK1995057 pretreatment attenuated this response, a similar 
GSK1995057 treatment effect was not apparent in human 
BAL taken 6 hours after LPS challenge in the clinical trial. 
BAL protein levels were not significantly increased in humans 
at 6 hours after LPS challenge, suggesting limited alveo-
lar-capillary leak in response to pulmonary LPS challenge at 
this early time point. We were unable to assess the contribu-
tion of TNFR2 signalling in these studies, primarily due to 
a paucity of specific biomarkers associated with the TNFR2 
pathway. Although we were unable to include a non-selective/
pan-TNF-α inhibitor antibody as a comparator in our clinical 
trial, the observed effects of GSK1995057 on neutrophilic 
infiltration appear similar to the effects of the long-acting anti-
TNF-α antibody adalimumab in the same model.40 Although 
neutrophil infiltration is a hallmark of ARDS pathophysiology, 
neutrophils are also likely to be important contributors to lung 
immunity, particularly in infectious causes of ARDS, and there-
fore the impact of therapies that modulate neutrophilia will 
need to be assessed carefully, in a stepwise manner. This small 
trial also only investigated a single, relatively high dose of 
GSK1995057 in male subjects. Further work to explore dose–
response relationships in both men and women is required to 
support generalisability. However, data from the investigation 
in monkeys suggest GSK199507 may be efficacious at much 
lower nebulised doses, further supporting the utility of low 
doses of inhaled dAbs for the treatment of pulmonary diseases. 
Finally, in our studies, GSK1995057 was administered prior 
to the LPS challenge, which may impact the translation of our 
findings to patients since most patients with ARDS would be 
treated after the initial injury. However, at this early stage of 
investigation, confirming primary pharmacology of this novel 
selective TNFR1 antagonist in a clinically relevant model was 
an important step in determining the potential of this therapy 
in ARDS. Moreover, since the evolution of ARDS is often 
predictable,41 and ongoing injury, for example, at the onset of 
mechanical ventilation, is also likely to occur,42 43 our studies 
support the potential utility of GSK1995057 for prophylaxis 
or early treatment of ARDS.
In summary, our data suggest that selective antagonism of 
TNFR1 using an inhaled dAb may offer therapeutic benefit in 
patients with ARDS, a common and devastating condition that 
currently has no effective disease-modifying therapy. While the 
clinical effectiveness of this approach in established disease is 
yet to be tested, a phase IIa clinical trial of a TNFR1-targeting 
dAb in patients is currently under way.
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